Clinical Use and Optimal Cutoff Value of Ca15-3 in Evaluation of Adnexal Mass Retrospective Cohort Study and Review of the Literature

被引:5
作者
Sagi-Dain, Lena [1 ,2 ]
Lavie, Ofer [1 ]
Auslander, Ron [1 ]
Sagi, Shlomi [1 ]
机构
[1] Bnai Zion Med Ctr, Dept Obstet & Gynaecol, Haifa, Israel
[2] Bnai Zion Med Ctr, Carmel Med Ctr, Genet Inst, Haifa, Israel
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2018年 / 41卷 / 09期
关键词
cancer antigen 15-3; ovarian mass; ovarian cancer; ovarian malignancy; OVARIAN-CANCER; TUMOR-MARKER; CA; 15-3; CA-15-3; MULTIPLE; MALIGNANCY; CARCINOMA; DIAGNOSIS; CA-125; PERFORMANCE;
D O I
10.1097/COC.0000000000000383
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To estimate the diagnostic performance and reference values of serum cancer antigen (Ca) 15-3 levels in the triage of adnexal masses. Materials and Methods: This retrospective cohort study was carried out in 481 patients referred to the Gynecology Department at Carmel Medical Center due to adnexal mass between years 2005 and 2012. All patients underwent surgery with histopathologically confirmed diagnosis and routine preoperative measurements of serum Ca125 and Ca15-3. Results: Combination of Ca125 with Ca15-3 elevated the sensitivity of Ca125 alone (from 86.9% to 93.2%; P = 0.029), along with reduction of its specificity (from 80.5% to 69.5%; P = 0.005) in differentiation between malignant and benign cases. According to receiver operating characteristic curve, Ca15-3 level of 21 U/mL was shown to be the optimal reference value for malignancy detection. All cases with Ca15-3 levels above 44.5 U/mL were malignant, mostly of primary ovarian source. Conclusions: As Ca15-3 assessment allowed detection of significantly more malignancy cases, we believe that measurement of this marker in combination with Ca125 is worthwhile in patients presenting with adnexal masses. The cutoff of 21 U/mL seems to be the optimal value in this specific population. High Ca15-3 levels (above 44.5 U/mL) strongly direct to a diagnosis of malignancy, mostly of primary ovarian tumors rather than breast malignancy.
引用
收藏
页码:838 / 844
页数:7
相关论文
共 42 条
[1]   Tumor markers in endometriosis [J].
Abrao, MS ;
Podgaec, S ;
Pinotti, JA ;
de Oliveira, RM .
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 1999, 66 (01) :19-22
[2]  
Al Musalhi Khawla, 2016, Oman Med J, V31, P336, DOI 10.5001/omj.2016.68
[3]  
[Anonymous], 2011, Obstet Gynecol, V117, P742, DOI 10.1097/AOG.0b013e31821477db
[4]   Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors? [J].
Ayhan, Ali ;
Guven, Suleyman ;
Guven, Emine Seda Guvendag ;
Kucukali, Turkan .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2007, 86 (04) :484-490
[5]  
BARRENETXEA G, 1990, European Journal of Gynaecological Oncology, V11, P369
[6]   New tumor markers: CA125 and beyond [J].
Bast, RC ;
Badgwell, D ;
Lu, Z ;
Marquez, R ;
Rosen, D ;
Liu, J ;
Baggerly, KA ;
Atkinson, EN ;
Skates, S ;
Lokshin, A ;
Menon, U ;
Jacobs, I ;
Lu, K .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2005, 15 :274-281
[7]  
BAST RC, 1991, CANCER-AM CANCER SOC, V68, P1758, DOI 10.1002/1097-0142(19911015)68:8<1758::AID-CNCR2820680819>3.0.CO
[8]  
2-#
[9]   Serum tumor marker immunoassays in gynecologic oncology: Establishment of reference values [J].
Bon, GG ;
Kenemans, P ;
Verstraeten, R ;
vanKamp, GJ ;
Hilgers, J .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1996, 174 (01) :107-114
[10]  
BOSTWICK DG, 1986, CANCER-AM CANCER SOC, V58, P2052, DOI 10.1002/1097-0142(19861101)58:9<2052::AID-CNCR2820580916>3.0.CO